An alpha-fetoprotein-maytansine conjugate for the treatment of AFP receptor expressing tumors....For ACT-903, tumors continued shrinking even after treatment completion, becoming undetectable in 9 of 10 animals….The efficacy and tolerability of ACT-903 in an animal tumor model supports advancing this conjugate toward clinical use with a regimen of either once a week or once every other week administration.